BRMS1L Inhibitors
BRMS1L inhibitors encompass a range of compounds that indirectly attenuate the ability of BRMS1L to repress gene transcription. The primary mechanism by which these inhibitors operate is through the modulation of histone acetylation levels. By preventing the removal of acetyl groups from histones, these inhibitors facilitate a chromatin conformation that is less compact and more permissive to transcription. This state of open chromatin directly contradicts the function of BRMS1L, which typically acts to compact chromatin and suppress gene expression. The actions of these inhibitors result in an environment where the transcriptional repression typically exerted by BRMS1L is counteracted, leading to the expression of genes that would otherwise be silenced. Given that BRMS1L functions as a transcriptional repressor, the elevation in histone acetylation effectively diminishes BRMS1L's capacity to impose its repressive influence on target genes.
The biochemical landscape influenced by BRMS1L inhibitors is characterized by increased histone acetylation, which impedes BRMS1L's repression of gene expression. These inhibitors selectively target histone deacetylase enzymes, leading to hyperacetylation of histones and a subsequent reduction in the repressive activity of BRMS1L. Through this action, the inhibitors create a chromatin structure that promotes gene expression, thereby indirectly inhibiting the repressive function of BRMS1L. Moreover, the selective inhibition of specific histone deacetylases can lead to differential effects on gene expression, as certain genes may be more sensitive to changes in histone acetylation patterns than others. This selectivity provides the potential for fine-tuning the expression of genes that are under the regulatory purview of BRMS1L. The consequences of such an inhibition can have far-reaching implications for cellular processes, including differentiation, proliferation, and apoptosis, which are often tightly controlled by epigenetic modifications.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
This histone deacetylase inhibitor increases acetylation levels of histones, leading to an open chromatin structure and facilitating transcription. BRMS1L function could be indirectly inhibited due to the increased expression of genes that counteract its transcriptional repression activity. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $88.00 $208.00 | 24 | |
As a selective inhibitor of class I histone deacetylases, this compound promotes acetylation of histones, which can reduce the ability of BRMS1L to repress transcription by altering chromatin accessibility. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
This HDAC inhibitor leads to the hyperacetylation of histones, which may counteract BRMS1L's ability to compact chromatin and repress gene expression, effectively inhibiting its function. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $196.00 | 9 | |
By inhibiting a broad spectrum of histone deacetylase enzymes, this compound prevents deacetylation of histones, potentially opposing BRMS1L's transcriptional repression by promoting a transcriptionally permissive chromatin state. | ||||||
(S)-HDAC-42 | 935881-37-1 | sc-296364 sc-296364A | 1 mg 5 mg | $94.00 $409.00 | ||
This HDAC inhibitor can alter gene expression patterns by changing histone acetylation status, which may lead to the inhibition of BRMS1L's repressive impact on gene expression due to a more open chromatin conformation. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $214.00 $622.00 | 1 | |
As a selective HDAC1 and HDAC2 inhibitor, it increases histone acetylation, potentially disrupting BRMS1L's repressive function on specific genes by modifying the structure of chromatin. | ||||||
Belinostat | 414864-00-9 | sc-269851 sc-269851A | 10 mg 100 mg | $153.00 $561.00 | ||
This HDAC inhibitor increases acetylation levels, which may inhibit BRMS1L's ability to compact chromatin and repress transcription by promoting an active chromatin state. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $85.00 | 9 | |
By inhibiting histone deacetylase, this compound could prevent BRMS1L from exerting its transcriptional repression by facilitating a more transcriptionally active chromatin structure. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $30.00 $46.00 $82.00 $218.00 | 18 | |
As a histone deacetylase inhibitor, it can promote histone acetylation, potentially counteracting the repressive transcriptional activity of BRMS1L by inducing a chromatin state that supports gene expression. | ||||||
D,L-Sulforaphane | 4478-93-7 | sc-207495A sc-207495B sc-207495C sc-207495 sc-207495E sc-207495D | 5 mg 10 mg 25 mg 1 g 10 g 250 mg | $150.00 $286.00 $479.00 $1299.00 $8299.00 $915.00 | 22 | |
This compound indirectly affects histone deacetylases, which can lead to an increase in histone acetylation levels, thereby inhibiting BRMS1L's ability to repress gene transcription by altering chromatin structure. | ||||||